Medifast (MED) Down 5.1% Since Last Earnings Report: Can It Rebound?

Medifast (MED) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 3, 2026

Is MEDIFAST (MED) Stock Outpacing Its Consumer Staples Peers This Year?

Here is how Medifast (MED) and New York Times Co. (NYT) have performed compared to their sector so far this year.

Zacks Investment Research • Jun 2, 2026

Medifast Confirms Appointment of Nicholas Johnson as Chief Executive Officer

BALTIMORE--(BUSINESS WIRE)--Medifast, Inc. (NYSE: MED) today announced that its Board of Directors has formally appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026. Johnson will succeed Dan Chard as CEO, who will continue to serve as Chairman of the Board. The appointment follows the leadership transition plan that the company disclosed in January and reflects the Board's confidence in Johnson's leadership and the company's strategic direction. Chard will remain active.

Business Wire • May 26, 2026

Weight Loss Coaching vs. App-Only Programs: What Published Research Shows About Long-Term Outcomes

70% of users discontinued use of lifestyle behavior and health apps within the first 100 days (Kidman PG, et al., 2024) Early weight loss at week four is a strong predictor of clinically relevant outcomes, with research identifying additional counseling and support as key for those showing lower early progress (Coleman CD, et al.

GlobeNewsWire • May 21, 2026

The Human Layer in Weight Management: What OPTAVIA's Coaching Model Is Built to Do

A randomized controlled trial published in Obesity Science & Practice found that clients on the OPTAVIA Optimal Weight 5 & 1 Plan® who worked with a coach lost significantly more weight and fat than those who attempted the program without coaching support (Arterburn LM, et al., 2019) Higher retention in a weight management program is directly correlated with more significant weight loss outcomes, per a 2024 systematic review and meta-analysis OPTAVIA coaches complete a program-specific education curriculum and must pass a certification exam before supporting participants Independent research commissioned by OPTAVIA found that 96% of Americans recognize lifestyle changes are essential for weight loss and management, yet only 17% feel confident they can manage it alone BALTIMORE, MD, May 21, 2026 (GLOBE NEWSWIRE) -- OPTAVIA, a science-backed, coach-guided comprehensive metabolic health system, is built around a core principle: that structured human support changes outcomes.

GlobeNewsWire • May 21, 2026

Peer-Reviewed Research Shows Structured Meal Replacement Programs Support Visceral Fat Reduction and Lean Mass Preservation

Body composition, specifically visceral fat levels and lean mass, plays a meaningful role in long-term metabolic health (Serra MC, et al., 2019) Structured plans, habit building, and dedicated coach support work together to produce body composition outcomes that reflect the quality of weight loss, not just its quantity (Arterburn LM, et al.

GlobeNewsWire • May 15, 2026

Peer-Reviewed Research Is Redefining Weight Loss Program Standards

The global weight loss industry was valued at $16.3 billion in 2025, yet peer-reviewed clinical validation of program outcomes remains uneven across the category Randomized controlled trials control for the lifestyle variables and selection bias that self-reported program data cannot account for, making them the standard for evaluating whether a weight loss program itself is driving outcomes Body composition is the breakdown of fat, lean mass, and bone. It shows what weight loss is actually made up of, a distinction that scale weight alone cannot capture A coach can address the specific barriers that may cause program adherence to stall, providing an additional support compared to digital trackers and tools BALTIMORE, MD, May 15, 2026 (GLOBE NEWSWIRE) -- Client experiences and peer-reviewed research are two pillars of evidence that, at their best, reinforce each other.

GlobeNewsWire • May 15, 2026

Why Medifast's $15 Cash Per Share Makes It A Strong Buy

Medifast trades below net cash value, with $15 per share in cash versus a $12.60 share price, creating a compelling value floor. Coach productivity surged 19% YoY to $5,432 per coach, signaling early signs of operational turnaround despite a shrinking coach base. Cost-cutting initiatives, asset sales, and a positive operating cash flow position MED for potential profitability by Q4 2026, with a $30 million savings target.

Seeking Alpha • May 13, 2026

Medifast: Worth Putting On A Watchlist

Medifast has continued to report concerning financials. A shrinking coach network lowers revenues, and costs remain too high. A turnaround can't be written off quite yet. MED's coach productivity has improved clearly, and a shift to a metabolic health focus from weight loss could work out. Negative enterprise value clearly implies upside potential; I estimate 47% upside to $18.50 if the company's earnings stabilize over the mid-term. Such upside is speculative, though.

Seeking Alpha • May 12, 2026

Medifast Q1 Loss Narrower Than Expected, Revenues Decline Y/Y

MED beats first-quarter estimates despite steep revenue declines, while stronger coach productivity and a new product launch support recovery hopes.

Zacks Investment Research • May 5, 2026